Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 76 to 90 of 264 results for carcinoma

  1. Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer untreated with BCG ID6454

    In development Reference number: GID-TA11592 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Hepatitis B (chronic): diagnosis and management (CG165)

    This guideline covers assessing and managing chronic hepatitis B in children, young people and adults. It aims to improve care for people with hepatitis B by specifying which tests and treatments to use for people of different ages and with different disease severities.

    Clinical guideline
    Last updated
    20 October 2017
    View recommendations

    Sections for CG165

  3. Breast cancer (QS12)

    This quality standard covers the care of people with breast cancer after they have been referred to a specialist team. It includes the management of early (ductal carcinoma in situ and invasive), locally advanced and advanced breast cancer; recurrent breast cancer; and familial breast cancer. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    16 June 2016
    View quality statements

    Sections for QS12

  4. Radical treatment of squamous cell carcinoma of the oesophagus:- Does the addition of surgery to chemoradiotherapy improve disease-free and overall survival inpeople with squamous cell carcinoma of the oesophagus?

    ID NG83/1 Question Radical treatment of squamous cell carcinoma of the oesophagus:- Does the addition of surgery to chemoradiotherapy...

    Research recommendation
    Published
    13 November 2018

  5. Tislelizumab for untreated unresectable hepatocellular carcinoma [TSID10683]

    Awaiting development Reference number: GID-TA11053 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Entecavir for the treatment of chronic hepatitis B (TA153)

    Evidence-based recommendations on entecavir for treating chronic hepatitis B in adults.

    Technology appraisal guidance
    Published
    27 August 2008
    View recommendations

    Sections for TA153

  7. SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound imaging of the liver (HTG291)

    Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver.

    HealthTech guidance
    Published
    29 August 2012
    View recommendations

    Sections for HTG291

  8. Ex-vivo hepatic resection and reimplantation for liver cancer (HTG190)

    Evidence-based recommendations on ex-vivo hepatic resection and reimplantation for liver cancer. This involves removing the liver from the body, cutting away the diseased tissue, and reimplanting the remaining tumour-free liver into the patient.

    HealthTech guidance
    Published
    22 April 2009
    View recommendations

    Sections for HTG190

  9. Past appeals and decisions

    Past technology appraisal appeals and decisions

  10. Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]

    In development Reference number: GID-TA11116 Expected publication date:  29 July 2026

    Technology appraisal guidance
    In development

  11. Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma [TSID10736]

    Awaiting development Reference number: GID-TA11076 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Research on second-line treatments for transitional cell carcinoma of the urothelial tract is needed. It noted that the vinflunine studies were the only studies in patients with transitional cell carcinoma of the urothelial tract whose disease had progressed after platinum-based chemotherapy. It was noted that there is a lack of evidence for the relative effectiveness of treatment options at this stage in the pathway of care. It is recommended that studies be undertaken to investigate the relative safety and efficacy of second-line treatments for transitional cell carcinoma of the urothelial tract, particularly randomised controlled trials.

    Question Research on second-line treatments for transitional cell carcinoma of the urothelial tract is needed. It noted that the...

    Research recommendation
    Published
    9 June 2015

  13. Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]

    In development Reference number: GID-TA10251 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Cosibelimab for treating advanced cutaneous squamous cell carcinoma [ID6663]

    Awaiting development Reference number: GID-TA11883 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer (HTG499)

    Evidence-based recommendations on electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer in adults. This involves using a small electrical current to improve the effect of chemotherapy given directly into the bladder.

    HealthTech guidance
    Published
    30 January 2019
    View recommendations

    Sections for HTG499